Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
78 hedge funds and large institutions have $479M invested in Mirati Therapeutics, Inc. Common Stock in 2015 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 31 increasing their positions, 15 reducing their positions, and 13 closing their positions.
107% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 15
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
92% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 13
38% more capital invested
Capital invested by funds: $346M → $479M (+$132M)
19% more call options, than puts
Call options by funds: $2.51M | Put options by funds: $2.1M
18% more funds holding
Funds holding: 66 → 78 (+12)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$14.6M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$13.7M |
| 3 |
VAM
Visium Asset Management
New York
|
+$12.8M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$11.1M |
| 5 |
Citigroup
New York
|
+$10.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$13.3M |
| 2 |
DM
Deerfield Management
New York
|
-$8.69M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$5.11M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$4.51M |
| 5 |
First Eagle Investment Management
New York
|
-$1.98M |
MRTX Hedge Fund Activity: Q3 2015 in Review
78 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q3 2015, worth a combined $479M — up 38% from $346M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new MRTX positions and 13 closed out — a net gain of 12 holders — while 31 added to existing stakes and 15 trimmed.
The largest buyer was RTW Investments, opening a new position worth an estimated $14.6M. The largest seller was OrbiMed, cutting an estimated $13.3M.
- 78 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q3 2015, up from 66 in Q2 2015.
- Funds reported $479M of Mirati Therapeutics, Inc. Common Stock stock for Q3 2015, up 38% quarter-over-quarter.
- 25 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q3 2015 and 13 closed out, a net change of +12 holders.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q3 2015 was RTW Investments, an estimated $14.6M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q3 2015 was OrbiMed, an estimated $13.3M sold.
Based on aggregated 13F filings for Q3 2015.